The muscle-type isozyme of rat 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is encoded by a mRNA transcribed from the M promoter of a 55-kb gene, which also produces the liver-type isozyme from an alternative promoter. By transient transfection and in vitro protein-DNA binding assays we have delineated, within 4.7 kb of 5' flanking sequence, the M promoter proper and an enhancer located between -1615 and -1809. This enhancer stimulated up to 12-fold the activity of the promoter in the context of an intact 5' flanking sequence and close to 900-fold the activity of the minimal (+41 to -40) M promoter cloned directly downstream from it. A functional dissection of the enhancer by site-directed mutagenesis and use of oligonucleotides suggested that its activity involves the cooperative effect of six binding sites for transacting factors clustered within 150 bp. These sites contain either an EF-1A/E4TF1 motif (also known to bind the ets oncogene product) or a Sp1 motif, or both. T...
INTRODUCTION
The expression of genes that encode rate-limiting or regulatory enzymes can be regulated through the use of alternative promoters. Different primary transcripts of the same gene typically encode isozymes that share the same catalytic core but differ by a regulatory domain often corresponding to the first exon, as in glucokinase (1) and pyruvate kinase (2) . A case in point is 6-phosphofructo-2-kinase (EC 2.7.1.105, PFK-2)/ fructose-2,6-bisphosphatase (EC 3.1.3.46, FBPase-2), a bifunctional enzyme that catalyzes the synthesis and degradation of fructose-2,6-bisphosphate. The latter is the most potent stimulator of 6-phosphofructo-1-kinase, hence of glycolysis (for a review, see ref. 3 ). There are several isozymes of GenBank accession no. M26215
PFK-2/FBPase-2. The muscle-type (M) isozyme has an amino acid sequence identical to that of the liver-type (L) isozyme, which has 470 residues, except for the first 32 residues which are replaced by a decapeptide in the M isozyme (4) . This difference leads to a 10-fold decrease in PFK-2/FBPase-2 activity ratio and a loss of the site of phosphorylation by cyclic AMP-dependent protein kinase which, in the L isozyme, inactivates PFK-2 and activates FBPase-2 (3).
We have characterized a 55-kb rat gene (gene A), containing 15 exons, that encodes the M and L isozymes of PFK-2/FBPase-2 by alternative use of two promoters, referred to as M and L promoters (5) . The M and L mRNAs share the same 13 exons. They begin with an additional, coding, exon which is specific for either the M isozyme (first exon of the gene, corresponding to the N-terminal decapeptide) or the L isozyme (second exon of the gene). This organization, together with the strategic position of PFK-2/FBPase-2 isozymes for integrating hormonal and metabolic signals in the control of glycolysis (3), prompted us to investigate the mechanisms involved in the transcriptional regulation of the gene. Work on the L promoter has been presented earlier (6) . We have now explored by transient transfection the cis-acting elements over 4.7 kb upstream from exon 1, namely upstream from the transcription initiation site of the M-type mRNA. The putative trans-acting factors were studied by in vitro DNase I footprinting, band-shift, and methylation interference assays. This led to the delineation of the upstream proximal elements of the M promoter and to the identification of a potent enhancer which acts by binding a unique combination of ubiquitous factors.
MATERIALS AND METHODS

Cell cultures
Rat hepatoma FTO2B cells were grown as monolayers in a mixture (1:1) of Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 medium, supplemented with 2 mM glutamine and 10% fetal calf serum. Rat hepatoma HTC cells were grown in suspension culture in Swim's-S77 medium supplemented with 10 mM glucose and 10% newborn calf serum. Fibroblastic Rat-l cells were grown in DMEM supplemented with 5% newborn calf serum. Rat (L6) and mouse (C2C12) skeletal muscle cell lines were grown in DMEM supplemented with 20 mM glucose and 20% fetal calf serum. Myogenic differentiation was induced by transferring confluent undifferentiated cultures to DMEM containing 2% horse serum (differentiation medium).
Plasmids and oligonucleotides All p2KMluc plasmids contain an M promoter fragment cloned upstream from the firefly luciferase reporter gene of pXP2 (7) . All constructs with 5' deletions have the same 3' end at nucleotide +41 relative to the major cap site of the M-type mRNA (5) . This 3' end was reconstitued by ligating the X20 BamHI-Haell (-1253/+7) genomic fragment (5) to a double stranded oligonucleotide corresponding to the sequence from + 8 to +41 with a 3' added XAoI site, and by cloning this construct into the BamHI and XhoI sites of the pXP2 polylinker. All 5' deleted constructs were derived by standard procedures from the construct described above (-1253/+41) or, for p2KM4700luc and p2KM2400luc, from this construct plus the appropriate fragment of the X20 genomic clone (5) . The numbering of the plasmids corresponds to the position of the restriction site used to make the 5' end, which was filled in with Klenow fragment or digested by mung bean nuclease (HphI site at -91), and ligated into the SmaI site of the pXP2 polylinker. Enhancer fragments were subcloned in one of the remaining restriction sites of the polylinker upstream from the M promoter TATA box (p2KM40luc) or upstream from the herpes simplex virus thymidine kinase (tk) gene promoter, namely the BamHI-BglII fragment of pBLCAT2 (8) , inserted into the BglII site of pXP2. In the denomination of the plasmids, letters between brackets refer to the restriction sites used to isolate the enhancer fragment.
Synthetic Transfection and enzymes assays Cells were transfected by the calcium phosphate method (10) with 10 1tg of supercoiled test plasmid and 1 or 2 ,ug of pRSV,Bgal as an internal control, per 60 mm-diameter dish. FTO2B and Rat-I cells were incubated overnight with the calcium phosphate precipitate and washed with phosphate-buffered saline before adding fresh medium. The cells were harvested 24 h later. L6 myoblasts were incubated for 5 h with the calcium phosphate precipitate, washed with DMEM and harvested after an additional 24 h in fresh medium as undifferentiated myoblasts. At the time of harvesting myoblasts, the medium of parallel sets of cultures was replaced by differentiation medium and the cells were cultured for an additional 96 h to obtain myocytes. Luciferase and I3-galactosidase activities were measured as described (6) . Background luciferase activity values obtained with pXP2 were 7 to 15 U in FTO2B cells and 10 to 50 U in L6 cells. Maximal values of 70,000 U in FTO2B cells and 200,000 U in L6 cells were obtained with enhancer test plasmids. Relative activities were calculated from the ratio of luciferase to ,B-galactosidase activity in each cell extract.
DNA-protein binding assays Nuclear extracts from HTC, L6, and C2C12 cells were prepared as described (11) with modifications (12) for the muscle cell lines. Skeletal muscle extracts (12) and nuclear extracts from rat liver and whole extracts from FT02B cells (6) were prepared as described. For DNase I footprinting, 10 to 20 jAg of proteins were incubated for 20 min at 0°C in 50 ,ul containing 10 mM Hepes (pH 7.9), 50 mM KCl, 5 mM MgC12, 0.05 mM EDTA, 0.5 mM dithiothreitol, 10% glycerol, 1 ,ug poly(dIdC), 2% polyvinyl alcohol and 10,000 to 20,000 cpm of 3' end 32P-labeled probe. Fifty yd of a 5 mM CaCl2, 10 mM MgCl2 solution were added and the samples were treated with various concentrations of DNase I for 1 min at 20°C. The reaction was stopped by adding 100 jd of stop buffer (200 mM NaCl, 20 mM EDTA and 1% sodium dodecyl sulfate). After extraction with phenol-chloroform and ethanol precipitation, samples were analysed on 6 or 8% polyacrylamide sequencing gels. For gel retardation assays, the binding reaction (20 IL) was performed in the same buffer as for DNase I footprinting, except that polyvinyl alcohol was omitted. One to 5 yg of proteins were preincubated for 10 min at 0°C with I to 3 ytg of poly(dIdC) before addition of competitor and labeled probe (5000 cpm). The incubation was continued for 20 min at 0°C and the samples were electrophoresed on a 5% polyacrylamide gel (40:1) in 6.7 mM Tris (pH 7.9), 3.3 mM sodium acetate, 1 mM EDTA, at 4°C and 200 V with recirculating buffer. Methylation interference assay was performed as described (13) 
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S. (17) of recombinant liver NF-1 (Fig. 2) . The position of the DNase I hypersensitive site on the noncoding strand with respect to the hemipalindrome was the same in sites I and II (Fig. 3) . We conclude that these sites most likely correspond to binding of NF-1, and that the affinity of this factor is lower for site II than for site I, consistent with the known role of neighboring sequences in NF-1 binding (18 (19) . It also includes a sequence that recognizes (18) DBP, a liverspecific protein (20) , and NF-IL6 (21) also called IL-6DBP (22) or LAP (23) .
The distal cis-acting sequence contains an enhancer To investigate the presence of an enhancer in the distal cis-acting sequence identified by 5' deletion (Fig. 1) , fragments of this sequence were cloned in the sense or antisense orientation upstream from the minimal (+41 to -40) PFK-2/FBPase-2 M promoter or from a heterologous (tk) promoter. These constructs were linked to the luciferase reporter gene and tested by transient transfection. FTO2B cells were used first because, in the *AGCTGGTTICCCC(41CC-T-*CTC*GCGTTTCCACCGCGTTCZQ&MGTCCCFTCCGCCCA.TCCGACGGCAGGACGCACGCWG-G-G-C-G-GG--4CTTCGAI bSee Fig. 4 .
CMean ratio * SEM of the activities obtained with the construct and with the corresponding promoter alone, for the number of independent experiments given in parentheses. -, not determined.
dMinimal PFK-2/FBPase-2 M-type promoter (p2KM40luc).
transfection experiments described in Fig. 1 To localize the enhancer more precisely, three subfragments of B-T were generated by restriction (Fig. 4) (Figs. 4 and 5) . Gel retardation assays with extracts from FTO2B and HTC cells, L6 myoblasts and myocytes, and liver, but not muscle showed a major complex (Fig. 6A) . The same complex was seen with C2C12 myoblasts and myocytes (not shown). In assays with FTO2B cell extracts, this complex was prevented by the competing fragment itself or by oligo B, which corresponds to the footprinted region. It was prevented neither by fragment H-Hpm in which the consensus b for EF-lA and d for SpI had been mutagenized, nor by oligo C which corresponds to the overlapping EF-lA consensus a and SpI consensus c, nor by a SpI consensus oligonucleotide (Fig. 7A) . When this enhancer fragment was methylated at single purines using dimethylsulfate and subsequently incubated with FTO2B cell extracts, three contact points were detected and they were located within the consensus b for EF-1A (Fig. 4) . This picture is incompatible with the known pattern of methylation interference produced by Spi (27) . These three points of methylation interference actually coincided with contact points identified by the same technique in the two EF-1A consensus of the adenovirus E1A core enhancer element using HeLa cell nuclear extracts (26) . Thus, the three types of assays used here indicate preferential factor binding in vitro to the EF-lA rather than the SpI consensus, and to the sense (b) rather than the antisense (a) EF-lA consensus in the H-Hp fragment.
As to the Hp-T fragment (-1615/-1675), it contains the SpI consensus a and b (Fig. 4) . No footprint was seen on this fragment with FTO2B cell extracts, consistent with the reported (27) low sensitivity of this method for detecting Spl binding. However, gel retardation assays showed two doublets typical of Spl binding with extracts from L6, C2C12, FTO2B or HTC cells, and from liver, but not from muscle (Fig. 6B) . With FTO2B cell extracts, these doublets were competed out by an Spl, but not by an USF, oligonucleotide (Fig. 7B) . Spl reportedly occurs as two variants (95 and 105 kDa) of the same polypeptide (28) . The occurrence of two Spl binding sites on this fragment could explain the presence of two doublets. These doublets were inhibited by the zinc-chelating agent, 1,10-phenanthroline, and this was counteracted by ZnSO4 (Fig. 7B) , as expected from the requirement for zinc fingers in the DNA binding activity of Spl (28) . These data are compatible with the binding of a Spl-like protein on the proximal half of the enhancer. Consistent with this, the enhancer fragment was active in both orientations (Hp-T versus T-Hp in Table 1 ) as is the case for Spl binding sites (27) .
Role of factor binding in enhancer activity These in vitro binding data suggest that two types of ubiquitous factors, namely EF-lA and a SpI-like protein, can interact with the enhancer. If factor binding where the consensus are overlapping is mutually exclusive, then the enhancer contains six potential sites of protein-DNA interactions, labeled I to VI in Fig. 4 . Further functional dissection of the enhancer was performed by reducing it to portions containing only one or two of these sites. This was achieved by determining how oligonucleotides or the mutagenized enhancer fragment H-Hpm would stimulate the minimal M promoter in transfection experiments. This promoter was preferred to the tk promoter with which stimulation was less dramatic. The mutation (H-Hp,.) was chosen to destroy the overlapping SpI and EF-lA consensus at site IV, because this site was the only one detectable by footprinting.
The results are shown in Table 1 . Together with those obtained with the enhancer fragments, these transfection data indicate that trans-activation in vivo may involve the cooperative binding of factors at each of the six sites. Indeed, oligo A (site V) which contains a single SpI consensus stimulated activity 2-fold, while fragment Hp-T which contains two SpI sites (I and II) stimulated activity 60-fold, suggesting that cooperative binding occurs at site I and site II. Fragment B-H namely site VI (EF-lA) stimulated promoter activity 3-fold, and oligo C namely site III (SpI/EF-lA in the same orientation) stimulated 6-fold. This cooperative model' would also account for the different sensitivity of the tk promoter and the minimal M promoter to the enhancer fragments ( Table 1) . The H-Hp fragment (-1744/-1675), which lacks sites I, II, and VI of the enhancer, lost about 60% of the activity of the intact enhancer when tested with the minimal M promoter, but retained full activity with the tk promoter. This is not surprising if one considers that the tk promoter contains two Spl and one NF-1 sites which could substitute for the cooperating enhancer binding sites missing from H-Hp fragment. Spl promoter sites have indeed been shown to cooperate with other Spl sites (29, 30) . By the same token, the Hp-T enhancer fragment (-1675/ -1615) which contains only sites I and II, the H-Hpm fragment which contains only sites III and V, and the B-H fragment (-1809/-1744) which contains only site VI, all retained more relative activity with the tk than with the minimal M promoter.
Finally, the transfection experiments showed that the function of the enhancer is not totally independent of distance and orientation effects. Indeed, the 900-fold stimulation seen in FTO2B cells when the enhancer was fused to the minimal M promoter was reduced to a 12-fold stimulation when it was located 1.7 kb upstream from it in the context of the intact 5' flanking sequence (Fig. 1) . Also, the enhancer core, which contains sites Ill, IV and V, was less active in the reverse (Hp-H) than in the right (H-Hp) orientation (Table 1) .
Enhancer activity in myoblasts and in myocytes As shown in Fig. 1 by transfecting 5' deletants in L6 cells, when the 5' flanking sequence was extended beyond -1498 there was an increase in relative luciferase activity in myoblasts but not in myocytes. To investigate whether the enhancer was inactive in myocytes, the activity of fragments of the region between -1498 and -1809 cloned upstream from the tk promoter or from the minimal M promoter was tested by transfection in L6 cells prior to or after differentiation (Table 1) .
In myoblasts, the enhancer was functional with the two promoters, albeit less so than in FTO2B cells. This lesser activity is consistent with the data in Fig. 1 . The limits of the enhancer were the same as in FTO2B cells since the fragment from -1498 to -1615 was inactive (not shown). The relative activity of the enhancer fragments tested in myoblasts was also in keeping with the corresponding results obtained in FTO2B cells (Table 1) . In myocytes, the enhancer and fragments thereof were as active as in myoblasts when tested with the M promoter, suggesting that the trans-acting factors specific for the enhancer were still present and active after differentiation. However, the relative activities measured for the enhancer (B-T) and for its middle (H-Hp) fragment when cloned upstream from the tk promoter were lower in myocytes than in myoblasts, as seen with the intact 5' flanking sequence. This difference was abolished by mutagenesis of site IV (see the H-Hpm fragment), suggesting that EF-IA is involved in this effect. These data also suggest that sequences present in the tk promoter or in the 5' flanking sequence outside the minimal M promoter cooperate with the enhancer to stimulate transcription more efficiently in myoblasts than in myocytes. An effect of serum per se in this difference is unlikely since stimulation of the tk promoter with the B-T fragment and with its H-Hp subfragment was as strong in the absence as in the presence of serum in FTO2B cells (not shown).
Consistent with the ubiquitous character of the enhancer binding factors described here, the relative activity of the enhancer (B-T) or of its middle (H-Hp) fragment cloned upstream from the tk promoter was as high in Rat-I fibroblasts as in L6 myoblasts (not shown). (20, 22, 23 (19, 32) . The distal half-site corresponds to a perfect consensus (5' AAAGG-TCA) for NGFI-B, also called nur/77, an early-response protein and orphan member of the nuclear receptor superfamily, which binds to a DNA sequence that contains only one half-site (33) . The significance of these receptor sites for the control of M-type inRNA transcription is unknown.
The regulatory sequences of genes expressed in muscle include motifs that are recognized by so-called muscle-specific transacting factors. The MEF-2, the CarG, the M-CAT, and the E boxes are representative of such motifs (34, 35 (39) . However, these interactions take place at -50 in the acetylcholine receptor gene i.e. immediately upstream from the TATA box, as is often the case for SpI binding (29) . Because Spl is a typical proximal promoter element, one cannot rule out the occurrence of an unidentified promoter in the vicinity of the enhancer described in this paper. This additional promoter need not contain a TATA box since the latter is often absent from GCrich promoters, where it is replaced by an initiator (Inr) sequence (40) . It might determine the synthesis of the PFK-2/FBPase-2 mRNA expressed in FT02B cells and L6 myoblasts. Indeed, although this mRNA contains exon 1, which is specific for the M isozyme, it appears to be slightly longer than the M-type mRNA (14) and therefore could contain (an) additional exon(s) upstream from exon 1. Even if (a) cryptic cap site(s) were present near the GC boxes, our data show that the B-T fragment contains regions that displayed enhancer properties. Thus, the enhancer could act on several promoters of the PFK-2/FBPase-2 gene A.
Indeed, Spl can act in vivo from enhancer sites that are as far as 1.8 kb from the promoter and exhibit synergistic interaction with promoter-proximal binding sites. This appears to rest on the ability of SpI to engage in homologous or heterologous protein-protein interactions through DNA looping (30) . Although Spl is ubiquitous, the potency of the enhancer may depend on the cell type because of the large tissue differences in Spl concentration and of possible effects of posttranslational modifications on Spl activity (37) .
Binding site redundancy and cooperation with other factors as described here is a known feature of Spl (29, 30) . To our knowledge, however, this is the first example of an association of SpI sites with EF-lA sites. EF-lA does not appear to be tissuespecific since it is present in human HeLa (cervix adenocarcinoma), 293 (embryonic kidney) and HepG2 (hepatoma) cell lines, in rat liver, and in mouse L (fibroblast) cells (26) . It transactivates the adenovirus ElA enhancer element I by binding to two cooperating motifs located at -300 and -270 (26) . EF-lA also binds to a similar motif at -140 in the adenovirus E4 transcriptional control region, in which case it was termed E4TFl (41). E4TF1 was purified from HeLa cells and shown to consist of at least two distinct subunits identified as a 60 kDa DNA-binding peptide and a 53 kDa transcriptional modulator peptide (42) . EF-lA also binds to the PEA-3 site of the polyoma virus A enhancer (26) . The latter site may be involved in the induction of this polyoma enhancer by the ets oncogene product, a potential member of the cell signalling network. Binding site IV in the enhancer described here contains a perfect consensus for the ets-1 binding sequence (18) , and binding sites HI and VI contain seven consecutive out of the eight bp of this consensus. E4TF1 binding sites have been described in the N-ras gene promoter region (43) and potential ets binding sites are found in the promoters of the so-called early response genes and of genes that are highly expressed in transformed cells (44) . Cell transformation, or stimulation by mitogens, is often accompanied by an increased PFK-2 activity and fructose-2,6-bisphosphate concentration. This might contribute to the so-called Warburg effect, namely the abnormally high glycolytic flux seen under these conditions (45, 46) . Whether this phenomenon involves increased transcription of the PFK-2/FBPase-2 gene studied here remains to be established. Still, the identification in this gene of an enhancer liable to possible control by the oncogene products of the ets family offers interesting working hypotheses.
